Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.

Uzun, SONER; Bilgiç Temel, ASLI; Akman Karakaş, AYŞE; Ergün, ERKAN; Özkesici, BİRGÜL; Eskiocak, ALİ; Erat, AYŞEGÜL; Uğurlu, NİLAY; Nazlım, BERNA; Koç, SALİHA; Bozkurt, SELEN; Dicle, ÖZLEM; Alpsoy, ERKAN; Yılmaz, ERTAN

doi:10.1111/ijd.13400

Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.

Copy For Citation

Uzun S., Bilgiç Temel A., Akman Karakaş A., Ergün E., Özkesici B., Eskiocak A. H., ...More

International journal of dermatology, vol.55, no.12, pp.1362-1368, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 55 Issue: 12
Publication Date: 2016
Doi Number: 10.1111/ijd.13400
Journal Name: International journal of dermatology
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1362-1368
Akdeniz University Affiliated: Yes

Abstract

BackgroundPemphigus vulgaris (PV) is a severe, chronic, and potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes. Rituximab is a monoclonal anti-CD20 antibody which has been used increasingly in the therapy of PV.